Datacentrex, Inc. (DTCX): Nasdaq/NYSE listing notice — Thumzup Media loses independent director; Nasdaq audit-committee compliance lapse

Datacentrex, Inc.

Director Robert Haag resigned from Board and all committees effective Oct 4, 2025; no disagreement cited.
Resignation left audit committee with fewer than 3 independent members, violating Nasdaq Rule 5605(c).
Nasdaq notified Thumzup of non-compliance on Oct 9, 2025; cure period runs until Oct 5, 2026 or next annual meeting.
Company plans to appoint an additional independent director to regain compliance before cure deadline.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Datacentrex, Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c), 5605(c)(4), 10A-3).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: audit committee
Rules: 5605(c), 5605(c)(4), 10A-3

Exact text from the filing

October 9, 2025, the Company was notified by Nasdaq of its non-compliance. Nasdaq Listing Rule 5605(c) requires, among other things, that the Company have an audit committee that has at least three members, each of whom must (i) be an Independent Director (as defined in Nasdaq Listing Rule 5605(a)(2)), (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, (iii) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Datacentrex, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-017646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.